Sumitomo Pharma Co (TSE:4506) Beneish M-Score: -1.50 (As of Jun. 27, 2026)


TSE:4506 Sumitomo Pharma Co Ltd TSE:4506
56 GF Score
Price 円1,444.00
GF Value 円827.78
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Beneish M-Score?

Sumitomo Pharma Co TSE:4506 -3.31% 56 Beneish M-Score is -1.50 as of Jun. 27, 2026. GuruFocus rates TSE:4506 with a GF Score™ of 56/100 and a GF Value™ of 円827.78 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Sumitomo Pharma Co ranks worse than 87.71% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.5 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Sumitomo Pharma Co's Beneish M-Score or its related term are showing as below:

TSE:4506' s Beneish M-Score Range Over the Past 10 Years
Min: -3.33   Med: -2.4   Max: -1.5
Current: -1.5

During the past 13 years, the highest Beneish M-Score of Sumitomo Pharma Co was -1.50. The lowest was -3.33. And the median was -2.40.


Sumitomo Pharma Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Beneish M-Score Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.36 -3.33 -2.98 -2.34 -1.50

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -2.32 -0.82 -1.59 -1.50

TSE:4506 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Beneish M-Score falls into.


TSE:4506
56GF Score
Sumitomo Pharma Co Ltd TSE:4506
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sumitomo Pharma Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.545+0.528 * 1.0857+0.404 * 1.0028+0.892 * 1.1366+0.115 * 1.1073
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7919+4.679 * 0.043688-0.327 * 0.8324
=-1.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円131,414 Mil.
Revenue was 105548 + 120624 + 119120 + 108002 = 円453,294 Mil.
Gross Profit was 54285 + 65187 + 73531 + 63890 = 円256,893 Mil.
Total Current Assets was 円279,252 Mil.
Total Assets was 円804,571 Mil.
Property, Plant and Equipment(Net PPE) was 円44,231 Mil.
Depreciation, Depletion and Amortization(DDA) was 円20,786 Mil.
Selling, General, & Admin. Expense(SGA) was 円162,557 Mil.
Total Current Liabilities was 円271,500 Mil.
Long-Term Debt & Capital Lease Obligation was 円179,056 Mil.
Net Income was -812 + 8817 + 87654 + 11206 = 円106,865 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = 円0 Mil.
Cash Flow from Operations was 29447 + 24243 + 18217 + -192 = 円71,715 Mil.
Total Receivables was 円74,840 Mil.
Revenue was 105649 + 112434 + 90074 + 90675 = 円398,832 Mil.
Gross Profit was 65978 + 70995 + 52696 + 55726 = 円245,395 Mil.
Total Current Assets was 円253,168 Mil.
Total Assets was 円742,604 Mil.
Property, Plant and Equipment(Net PPE) was 円46,648 Mil.
Depreciation, Depletion and Amortization(DDA) was 円25,562 Mil.
Selling, General, & Admin. Expense(SGA) was 円180,605 Mil.
Total Current Liabilities was 円240,603 Mil.
Long-Term Debt & Capital Lease Obligation was 円258,982 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(131414 / 453294) / (74840 / 398832)
=0.289909 / 0.187648
=1.545

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(245395 / 398832) / (256893 / 453294)
=0.615284 / 0.566725
=1.0857

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (279252 + 44231) / 804571) / (1 - (253168 + 46648) / 742604)
=0.597944 / 0.596264
=1.0028

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=453294 / 398832
=1.1366

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(25562 / (25562 + 46648)) / (20786 / (20786 + 44231))
=0.353995 / 0.319701
=1.1073

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(162557 / 453294) / (180605 / 398832)
=0.358613 / 0.452835
=0.7919

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((179056 + 271500) / 804571) / ((258982 + 240603) / 742604)
=0.559995 / 0.672748
=0.8324

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(106865 - 0 - 71715) / 804571
=0.043688

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sumitomo Pharma Co has a M-score of -1.50 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.50 mean?
Sumitomo Pharma Co (TSE:4506) has a Beneish M-Score of -1.50 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sumitomo Pharma Co and its competitors. According to the industry distribution chart, Sumitomo Pharma Co ranks #799 out of 911 companies in the Drug Manufacturers industry, placing it in the top 87.7%.
Is Sumitomo Pharma Co's Beneish M-Score too high?
Sumitomo Pharma Co's current Beneish M-Score is -1.50. Based on the distribution chart, Sumitomo Pharma Co ranks #799 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sumitomo Pharma Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #799 out of 911 companies for Beneish M-Score. This places Sumitomo Pharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Beneish M-Score is -1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円827.78, compared to a current price of 円1,444.00 — trading 74.4% above its estimated fair value. The current Beneish M-Score is -1.50. Sumitomo Pharma Co's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current Beneish M-Score is -1.50 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of 円1,444.00 is trading 74.4% above its estimated GF Value™ of 円827.78. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for TSE:4506:

  • Beneish M-Score: -1.50
  • GF Value™: 円827.78 vs. price of 円1,444.00 (74.4% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
56GF Score

Get the complete analysis for TSE:4506

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,444.00
Price
円827.78
GF Value